Abstract
Indonesian herbal medicines made from mixtures of several plants are called “Jamu.” The efficacy of a particular Jamu is determined by its ingredients i.e. the composition of the plants. Thus, we modeled the ingredients of Jamu formulas using Partial Least Squares Discriminant Analysis (PLS-DA) in order to predict their efficacy. The plants used in each Jamu medicine served as the predictors, whereas the efficacy of each Jamu provided the responses. Utilizing response predictions obtained from PLS-DA, we predicted the efficacies of Jamu formulations using two methods: maximum response prediction and maximum probability. In predictions of Jamu efficacy, the maximum response prediction method produced a smaller error than that the maximum probability method. Furthermore, utilizing the PLSDA coefficient matrix, we determined the efficacy for which a plant is most useful, based on its largest coefficients.
Keywords: Efficacy, Jamu, main ingredients, medicinal plant, multivariate analysis, PLS-DA, regression coefficient, response prediction, formulation, modelling
Current Computer-Aided Drug Design
Title:Efficacy Prediction of Jamu Formulations by PLS Modeling
Volume: 9 Issue: 1
Author(s): Farit M. Afendi, Latifah K. Darusman, Aki Hirai Morita, Md. Altaf-Ul-Amin, Hiroki Takahashi, Kensuke Nakamura, Ken Tanaka and Shigehiko Kanaya
Affiliation:
Keywords: Efficacy, Jamu, main ingredients, medicinal plant, multivariate analysis, PLS-DA, regression coefficient, response prediction, formulation, modelling
Abstract: Indonesian herbal medicines made from mixtures of several plants are called “Jamu.” The efficacy of a particular Jamu is determined by its ingredients i.e. the composition of the plants. Thus, we modeled the ingredients of Jamu formulas using Partial Least Squares Discriminant Analysis (PLS-DA) in order to predict their efficacy. The plants used in each Jamu medicine served as the predictors, whereas the efficacy of each Jamu provided the responses. Utilizing response predictions obtained from PLS-DA, we predicted the efficacies of Jamu formulations using two methods: maximum response prediction and maximum probability. In predictions of Jamu efficacy, the maximum response prediction method produced a smaller error than that the maximum probability method. Furthermore, utilizing the PLSDA coefficient matrix, we determined the efficacy for which a plant is most useful, based on its largest coefficients.
Export Options
About this article
Cite this article as:
M. Afendi Farit, K. Darusman Latifah, Hirai Morita Aki, Altaf-Ul-Amin Md., Takahashi Hiroki, Nakamura Kensuke, Tanaka Ken and Kanaya Shigehiko, Efficacy Prediction of Jamu Formulations by PLS Modeling, Current Computer-Aided Drug Design 2013; 9 (1) . https://dx.doi.org/10.2174/1573409911309010005
DOI https://dx.doi.org/10.2174/1573409911309010005 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin Bs, One Carbon Metabolism and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Current Drug Targets Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?
Current Molecular Pharmacology Synthesis and Cytotoxic Evaluation of Novel Symmetrical Taspine Derivatives as Anticancer Agents
Medicinal Chemistry Drug-Glycosidation and Drug Development
Mini-Reviews in Medicinal Chemistry Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets An Evaluation of the Antioxidant and Anticancer Properties of Complex Compounds of Copper (II), Platinum (II), Palladium (II) and Ruthenium (III) for Use in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Current Pharmacogenomics Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Image Fusion Based on Estimation Theory: Applied to PET/CT for Radiotherapy
Recent Patents on Medical Imaging Development and In Vitro Proof-of-Concept of Interstitially Targeted Zinc- Phthalocyanine Liposomes for Photodynamic Therapy
Current Medicinal Chemistry Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Epoch-making Treatment with Transoral Robotic Surgery for Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry miRNA: Small Molecules as Potential Novel Biomarkers in Cancer
Current Medicinal Chemistry